http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6455051-B1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_382ccfc2ebebcaee15aa7cda4cee86bc
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-217
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
filingDate 1998-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2002-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31f65abde6b505f43e2779cebfaa704e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_188286a15d1cee99c8f8e0c3fb80597d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e29eced3147c69841af0f3662f84239
publicationDate 2002-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-6455051-B1
titleOfInvention Ameliorant for hepatitis C therapeutic effect and application thereof
abstract The present invention provides an ameliorant for enhancing the therapeutic effect of IFN-alpha on hepatitis C; a therapeutic composition for the treatment of hepatitis C which comprises IFN-alpha and IFN-gamma as active ingredients and further contains a pharmaceutically acceptable carrier; a kit for the treatment of hepatitis C which comprises an IFN-alpha preparation and an IFN-gamma preparation; and a therapeutic method for the treatment of hepatitis C which comprises administering IFN-alpha and IFN-gamma to a subject at the same time or administering IFN-gamma before the administration of IFN-alpha. The present invention is capable of making the patient continuously HCV-RNA negative and is extremely useful in the treatment of chronic hepatitis C which is intractable with, IFN-alpha and conventionally difficult to remedy.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03030923-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005013801-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004078207-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009196853-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006018875-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005095224-A1
priorityDate 1997-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5082659-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0294160-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0790062-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0107498-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H09216831-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H07258109-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID107428
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID62825
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393819
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226405861
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226405557
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6251
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18594011
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226405558
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393712
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399846
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393714
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID439186
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID453
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6255
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21859
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226400908

Total number of triples: 43.